Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome - Wikidata - wikimedia - TriplyDB

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

http://www.wikidata.org/entity/Q24606843

about

Atypical hemolytic uremic syndrome Hemolytic uremic syndrome: new developments in pathogenesis and treatment Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN Advances and challenges in the management of complement-mediated thrombotic microangiopathies Hemolytic uremic syndrome Complement cascade and kidney transplantation: The rediscovery of an ancient enemy Complement System Part II: Role in Immunity Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network.Three kidneys, two diseases, one antibody?A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.Thrombotic microangiopathy and acute kidney injury following vivax malaria.Thrombotic microangiopathy and associated renal disorders.Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome STEC-HUS, atypical HUS and TTP are all diseases of complement activation.Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects.Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab.Complement disorders and hemolytic uremic syndrome.Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.Successful treatment of DEAP-HUS with eculizumab.Cardiovascular complications in atypical haemolytic uraemic syndrome.Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome.An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome.Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab.A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome.Extra-renal manifestations of complement-mediated thrombotic microangiopathies.Eculizumab hepatotoxicity in pediatric aHUS.The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.An international consensus approach to the management of atypical hemolytic uremic syndrome in children.Successful living-related renal transplantation in a patient with factor H antibody-associated atypical hemolytic uremic syndrome.The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies Anti-complement-factor H-associated glomerulopathies.Can eculizumab be discontinued in aHUS?: Case report and review of the literature

P2860

Q21202864-8CEE9DE6-569F-4418-9DE8-AEDFF4F7B4EC Q24613517-B8869073-1FBD-4B5E-8233-86E11CE68B5D Q26741542-D337EFD2-AC3E-49FA-A8C1-AFC4EDB23C68 Q26796453-08B0FC65-F08A-4972-A885-4F7B6798F1BE Q26799054-454F2543-0162-4734-B7BF-E2951E2B8523 Q26829790-E13040D7-CF26-4A02-8961-23ECBA858128 Q28263460-B8ABAB14-D726-4793-A391-093F45490A13 Q31010561-5A01C13B-AAB3-4747-8590-9B94B442168A Q33396530-AFB22344-0E35-4B3F-8C75-0EF8F620C8ED Q33399198-B1BCC3B4-CBD3-4023-A8CC-F464EED2D126 Q33402100-669877A8-BC13-4830-96B0-0485C627D07C Q33402372-A66CA7CA-7D83-4801-BA13-37E3FFF39DE3 Q33402827-AC66B93A-59B3-4C92-AA56-7963763BF910 Q33403359-B0E19FA5-D66A-4975-9DAE-165665ED19E6 Q33403607-3E499BED-0F67-41F1-8389-106DCC41B9E4 Q33404847-9F1FC494-AC3E-4EB7-8B49-37C97F252457 Q33404888-9AE21D86-5649-47E1-808F-FD261D3EE9F8 Q33405246-9C8E311B-F7A7-4AB4-A6C1-49605E3E989F Q33405522-C8A328A9-F1DF-4136-8C3B-13C5D53A4B45 Q33405726-FB0B3271-F3BB-4C6E-9F10-20EE6FB5CB12 Q33405802-7E534DB4-235D-425B-89FD-AA1029E64806 Q33406025-AE245D39-092B-4E55-B8CC-C588617104C8 Q33409198-84D0CCD5-39D6-4115-A009-AE0FBD0C7120 Q33411577-BA543F5E-710D-46B8-B938-BC242F017E6B Q33412640-80EA1FC8-FDA7-4481-BFA0-424D52D87EE3 Q33414109-6DBE53E1-FD05-4601-837B-A07E3D3E1D53 Q33415192-0DA90963-16A5-40AE-84B0-B2FF0D7FE101 Q33415218-0F214F81-43A1-4E28-BDDC-7C0ABD5DC3F5 Q33415314-008D956B-8897-42B2-8A96-D3952AA1C14A Q33415753-09FDBACB-2AE4-4C7A-8FBF-87218FE6EA03 Q33416830-B37908A8-2A5A-4322-885A-A68144F83B7F Q33417644-4E0B73F9-8CF5-4A05-ADB1-10C746F9C717 Q33417814-545AA4AC-05DB-484A-A52B-ECCDCF513905 Q33418797-26C09BC8-0A38-4F05-9C4C-3948FFC91BCB Q33420213-48BE8F52-AAE3-4045-AE20-76F815BD6FE8 Q33421861-95B9BF72-CA34-46F8-997E-DEF9F14BA9BB Q33423342-66198093-F49C-494E-BDF3-B9CAAE59B2B6 Q33427495-879092F4-A181-460A-ABF9-1DD866CD8F85 Q33434103-DB1581BF-B09F-44E1-8D0E-53A6A93FDC85 Q33434378-26FECCB7-EA11-4A3D-BE89-3731901396F7

P2860

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

http://www.wikidata.org/entity/Q24606843

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

@ast

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

@en

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

@nl

type

label

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

@ast

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

@en

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

@nl

prefLabel

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

@ast

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

@en

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

@nl

P1433

Q24606843-81FA191C-6649-4FE6-93E0-512A948611E3

P1476

Q24606843-5024EE5C-07B0-40C1-A7EA-F876DD70842B

P2093

Q24606843-0AEB871B-5AA1-4335-A9A7-8A9FC319E2E6

Q24606843-0B862D53-07AB-45AF-B5E7-A38BFBB281B7

Q24606843-22BCE069-81BD-4069-9CC5-426E8CA59F6E

Q24606843-71584959-EFA6-4B23-872F-ABE8216BDFEF

Q24606843-8C9A4209-4D59-43BA-8C02-E322B6B16515

Q24606843-9B0F24FC-5C39-4E4B-A4F0-DC5B7D1B92C9

Q24606843-D08EC274-340B-478F-9051-0F50A2859000

Q24606843-D55F0E30-0472-47A0-8970-B2012EE92F53

Q24606843-E33A5BCE-CD6E-427D-9BF1-1D73A9D13723

Q24606843-FCFD11EE-7EFF-4F6D-9339-10C19EF97BF1

P2860

Q24606843-13A1000B-2610-4CE9-899F-31E8A147E690

Q24606843-17BF9DAC-ABDE-4B54-AE5D-F4E39C0896DD

Q24606843-191BBA98-D90F-4480-A6C5-CE1FED84E913

Q24606843-19EABBF7-942A-42E8-9122-FF09096B9B9A

Q24606843-28C26451-CCAE-4021-9A47-43EE477BCE43

Q24606843-2BB881E0-9FAD-4AC0-8C0A-4DE12754F0AC

Q24606843-373D6347-52F2-49F2-90A0-15F5A4AFA44A

Q24606843-4B21FFAA-053F-4348-821D-093927B9BF34

Q24606843-56C04FE5-5B0F-48C3-9190-D6260E1D9828

Q24606843-57F546C7-D6DD-44C0-9F04-C0FD6B66D410

P304

Q24606843-E90E8BF1-7913-4C0D-A1FC-F5628F3B544F

P31

Q24606843-9B019B80-3143-4A62-8ADE-F7FA60A78206

P3181

Q24606843-77A108AF-4C0A-4B8F-9AA3-43AC99EE81FC

P356

Q24606843-BCC026CB-D631-4E9D-A1F0-9933FA3CCD5A

P407

Q24606843-1F1C307B-7CC0-4C4C-932D-5FE006A4A88E

P433

Q24606843-38B8820D-36FE-4114-A92C-5AF0F2906EB4

P478

Q24606843-49B00C37-69ED-4B8D-B4A1-1359770F6EB3

P50

Q24606843-27190722-DF95-4489-BC6C-811446B824C9

Q24606843-63D34DC0-7AFE-4E88-973C-18AEE28CA0BC

Q24606843-6E5C2EE9-2963-40A6-8224-810FC6CD887C

Q24606843-8370575A-7F91-407D-87D4-21E2506135A2

Q24606843-8F3ABB88-6B1A-4945-8256-DF2D6255EF7B

P577

Q24606843-82F855E0-1AE7-4FBB-9669-CD907380CF82

P698

Q24606843-BE25D0BA-0C58-4F64-B3A1-2099269533ED

P921

Q24606843-F7B6EDDD-4401-4F62-821B-363A01866242

P932

Q24606843-46408701-4006-40C8-8602-9A29D4B7E5E8

P3181

P356

P1433

Journal of the American Society of Nephrology

P1476

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

@en

P2093

Arvind Bagga

http://www.w3.org/2001/XMLSchema#string

Bruno Ranchin

http://www.w3.org/2001/XMLSchema#string

Caroline Blanc

http://www.w3.org/2001/XMLSchema#string

Hae Il Cheong

http://www.w3.org/2001/XMLSchema#string

Jacques Blouin

http://www.w3.org/2001/XMLSchema#string

Jean-Luc André

http://www.w3.org/2001/XMLSchema#string

Nobuaki Takagi

http://www.w3.org/2001/XMLSchema#string

Pankaj Hari

http://www.w3.org/2001/XMLSchema#string

Patrick Niaudet

http://www.w3.org/2001/XMLSchema#string

Sidharth Kumar Sethi

http://www.w3.org/2001/XMLSchema#string

P2860

Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

Population-based trends in pediatric hemolytic uremic syndrome in California, 1994-1999: substantial underreporting and public health implications.

Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

Childhood hemolytic uremic syndrome is associated with adolescent-onset diabetes mellitus.

Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.

P304

2180-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4379495

http://www.w3.org/2001/XMLSchema#string

P356

10.1681/ASN.2010030315

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Véronique Frémeaux-Bacchi

Moglie Le Quintrec

Wolf Hervé Fridman

Marie-Agnès Dragon-Durey

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21051740

http://www.w3.org/2001/XMLSchema#string

P921

P932

3014031

http://www.w3.org/2001/XMLSchema#string